Sonnet biotherapeutics announces pricing of $4.55 million underwritten public offering

Princeton, nj / accesswire / october 25, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("we," "us," "our," "sonnet" or the "company"), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 5,687,500 shares of common stock. each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with two investor warrants at a combined offering price of $1.60, for total gross proceeds of approximately $4.55 million, before underwriting discounts and commissions and offering expenses payable by sonnet.
SONN Ratings Summary
SONN Quant Ranking